Abstract
The global incidence of steatotic liver disease (SLD), driven by metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the synergistic metabolic dysfunction and alcohol-associated liver disease (MetALD), is fueling a rapid rise in hepatocellular carcinoma (HCC). Regardless of the initial etiology (metabolic, alcoholic, or viral), progression to advanced SLD and HCC is governed by critical shared pathways, which are systemic metabolic dysregulation and inflammation. Identifying a single, targeted pharmacological agent to address this unified pathophysiology is an urgent unmet need. This review addresses the epidemiological links between SLD etiologies and HCC, dissecting their shared metabolic pathophysiology. We evaluate the emerging potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a multifunctional therapeutic strategy to target this metabolic hepatic nexus. GLP-1 RAs offer a dual central and peripheral mechanism against SLD progression. Centrally, these GLP-1 RAs modulate appetite and reduce the intake and cravings for high-calorie food and alcohol. Peripherally, these agents induce significant weight loss, enhance insulin sensitivity, and reduce hepatic de novo lipogenesis. While their efficacy in resolving metabolic dysfunction-associated steatohepatitis (MASH) is increasingly well documented, their ability to target the metabolic hepatic nexus also suggests a promising therapeutic role in ALD and MetALD. Furthermore, GLP-1 RAs appear to exert direct anti-inflammatory and anticancer effects by activating metabolic sensors, such as the AMPK pathway, to inhibit proliferative signaling. Clinical and preclinical data support the efficacy of GLP-1 RAs in resolving steatosis and SLD progression in metabolic contexts. By targeting shared metabolic dysregulation, GLP-1 RAs emerge as potential candidates for HCC risk mitigation and may serve as future therapeutic adjuvants. Future large-scale, prospective clinical trials are warranted to confirm these benefits, particularly in ALD and MetALD, where underlying metabolic dysfunction remains a significant driver of disease progression.
1 Introduction
The global burden of steatotic liver disease (SLD), also known as fatty liver disease, is undergoing a profound epidemiological shift. It is rapidly moving away from viral hepatitis as the sole primary driver of chronic liver morbidity and mortality, and overwhelmingly towards conditions rooted in metabolic dysfunction (; ). This shift is driven by the parallel global epidemics of type 2 diabetes mellitus (T2DM) and obesity, which fuel the rise of metabolic dysfunction-associated steatotic liver disease (MASLD) (; ). Now recognized as the most common chronic liver condition globally, MASLD creates a niche for the development of advanced liver pathology, including cirrhosis and hepatocellular carcinoma (HCC) (; ). MASLD is estimated to affect over 30% of the worldwide population, with prevalence rates exceeding 70% in individuals with T2DM, underscoring the severity of this metabolic-hepatic nexus ().
This metabolic crisis is further complicated by alcohol-associated liver disease (ALD), an aggressive pathology resulting from excessive alcohol consumption. While ALD and MASLD were historically viewed as distinct entities, they share similar histology and some pathological mechanisms, most notably altered metabolic homeostasis in the liver and adipose tissue. More critically, the disease spectrum now includes metabolic dysfunction and alcohol-associated liver disease (MetALD), a recently classified subcategory (; ). In MetALD, the co-existence of metabolic risk factors (like obesity and T2DM) and moderate-to-high alcohol consumption creates a synergistic “double-hit” injury that accelerates disease progression and HCC risk significantly more than either factor alone. Collectively, the rising prevalence of MASLD, ALD and MetALD has made these conditions the fastest-growing cause of HCC and among the leading reason for liver transplantation worldwide (Ochoa-Allemant et al., 2025; ).
Furthermore, while chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain established risk factors for HCC, they also induce changes in lipid and glucose homeostasis. This suggests that even viral infections rely on a shared pathophysiological link through altered metabolism and the induction of SLD to drive carcinogenesis (Wang and Zhang, 2023; Wang J. et al., 2024; Nakamura et al., 2025). Given the central role of altered metabolism across virtually all major HCC etiologies, the development of potent pharmacotherapies that target metabolic dysfunction is an urgent priority.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising class of medications to address this underlying metabolic dysregulation that drives SLD. Initially developed for glycemic control in T2DM, GLP-1 RAs act as incretin mimetics by stimulating glucose-dependent insulin secretion and inhibiting glucagon release (; ). Beyond their effects on insulin secretion, accumulating evidence demonstrates that GLP-1 RAs also enhance insulin sensitivity and reduce systemic insulin resistance. More recent studies further highlight that these agents exert both central and peripheral actions, conferring a powerful dual mechanism of action. Centrally, GLP-1 RAs modulate reward pathways to reduce cravings for both high-calorie foods and alcohol (; ; ), key behavioral drivers of SLD. Peripherally, they improve insulin sensitivity, reduce hepatic lipotoxicity, and attenuate systemic and hepatic inflammation (; Skibicka, 2013). Clinical studies in patients with MASLD have shown that GLP-1 RA therapy is associated with clinically meaningful reductions in progression to metabolic dysfunction-associated steatohepatitis (MASH). Complementary preclinical studies in animal models demonstrate that GLP-1 RAs reduce alcohol craving and alcohol consumption, suggesting potential therapeutic benefit in alcohol use disorder (AUD). These central effects, together with their ability to ameliorate metabolic dysregulation observed in ALD, a condition for which the only established therapeutic options currently remain sustained abstinence or liver transplantation. This review aims to dissect the epidemiological and mechanistic links between altered metabolism and HCC across MASLD, ALD, and viral etiologies, summarize the current therapeutic landscape, and critically evaluate the emerging role of GLP-1 RAs as a strategic intervention for prevention and clinical management across this complex disease spectrum.
2 Global epidemiology and SLD progression to HCC
HCC is a significant global health threat, ranking as the fourth most common cancer and the second leading cause of cancer-related mortality worldwide (). The global rise in HCC incidence is strongly and disproportionately correlated with the epidemic rise of MASLD (; Shi et al., 2024). Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of MASLD characterized by inflammation and hepatocyte injury, is expected to overtake chronic hepatitis C as the most common indication for liver transplantation (; Younossi et al., 2021). Data from the last 2 decades reveal a dramatic increase in HCC attributable to MASH (). Alcohol consumption also remains an intractable risk factor, with heavy, long-term use contributing significantly to HCC and accounting for 30% of HCC cases and HCC-specific deaths (Patel and Mueller, 2025). This risk is further compounded in MetALD patients, where the coexisting metabolic syndrome and alcohol consumption establish a uniquely high-risk population driven by synergistic insults (Ochoa-Allemant et al., 2025; ). Regardless of the initial trigger (metabolic stress, alcohol, or virus), the disease typically progresses through a multi-step process: simple steatosis to steatohepatitis (MASH/severe ALD), to cirrhosis and HCC. Intervening at the steatosis or steatohepatitis stage is critical for effective prevention ().
3 Spectrum of SLD and mechanisms of progression to HCC
HCC predominantly arises in the setting of chronic liver injury, but the specific insults (metabolic excess, alcohol, or viral infection) converge upon a common pathogenic pathway: dysregulated hepatic metabolism. This dysregulated metabolism creates an environment characterized by persistent oxidative stress, chronic inflammation, and altered energy signaling, which collectively drive fibrosis and cellular transformation (; ; Ramaite and Nkadimeng, 2025). Understanding the specific metabolic alterations within each major etiology is key to target the disease with a compound, which can help metabolic homeostasis, such as GLP-1 R analogs (Wang and Lu, 2025; ; ).
3.1 Type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD)
The global epidemic of T2DM is inextricably linked to the rising burden of MASLD and HCC. Diabetes affecting over 830 million people, which accounts for 14% of adults 18 years or older worldwide (). Alarming projections indicate that its prevalence will increase by 25% in 2030 and 50% in 2045 (). As the dominant form of the disease, T2DM accounts for over 95% of diabetic patients and is largely attributable to the obesity pandemic (; ; Miller et al., 2025). Further, T2DM remains one of the most significant risk factors not only for the development of MASLD but also for the progression of liver fibrosis and the occurrence of liver‐related complications, including HCC (; ; Riley et al., 2024).
In the context of MASLD and T2DM, altered metabolism is the primary etiology. The root cause is systemic insulin resistance, typically driven by high calorie intake and positive energy balance (excess calories). This chronic caloric excess eventually overwhelms the storage capacity of visceral adipose tissue, leading to adipose tissue failure. Adipose tissue failure forces the spillover of excessive free fatty acids (FFA) into the systemic circulation, causing ectopic fat deposition in non-adipose organs, including the skeletal muscle and, critically, the liver (; Stefan et al., 2025; Tantu et al., 2025). These high circulating FFAs, alongside inflammatory adipokines released by dysfunctional fat tissue, impair insulin signaling and develop systemic insulin resistance. This insulin resistance affects the liver directly, promoting increased de novo lipogenesis and endogenous glucose production, thereby driving both hepatic steatosis and hyperglycemia.
The transition from simple steatosis to advanced liver disease is governed by a multi-parallel hit model against this backdrop of established insulin resistance. Hepatic lipotoxicity creates a pro-inflammatory environment that makes the liver highly susceptible to simultaneous insults, including mitochondrial dysfunction (generating oxidative stress), endoplasmic reticulum stress (Miller et al., 2025; Tantu et al., 2025; ) and the activation of innate immune cells (kupffer cells) by signals from inflammatory adipokines and endotoxins from the gut (due to gut dysbiosis). These parallel hits drive inflammation, hepatocellular ballooning, and subsequent fibrosis, forming the critical juncture that determines the risk of progression to cirrhosis and HCC.
Current management strategies include foundational interventions like calorie restriction and lifestyle modification, which are shown to improve MASLD treatment outcomes by addressing the root metabolic cause. Furthermore, hypoglycemic agents such as pioglitazone and empagliflozin exhibit beneficial effects on liver tissue outcomes, such as reducing liver fat content and improving liver fibrosis (; Miller et al., 2025; ; ; Pieralice et al., 2025), demonstrating that therapeutic targeting of the metabolic axis is effective.
3.2 Alcohol-associated liver disease (ALD)
Excessive alcohol use is a serious health concern globally, and after the brain, the liver sustains the greatest damage. ALD is a major health problem, accounting for 30% of HCC cases (). Ninety percent of individuals with excessive alcohol use develop steatosis, the earliest and most common response of the liver to excessive ethanol consumption. Compared to non-drinkers, heavy alcohol consumption has been associated with an 87% increased HCC risk (; Pan et al., 2025).
Central among the many mechanisms proposed to play a role in the development of ALD are impaired metabolic homeostasis and organ crosstalk. Studies have shown that impaired levels of insulin and an increase in insulin resistance lead to increased adipose lipolysis and FFA release into the circulation and their enhanced hepatic uptake, subsequently causing fat accumulation in the liver (Zhong et al., 2012; Wei et al., 2013; ; Rasineni et al., 2019a; ; Rasineni et al., 2019b). In addition to increased uptake of adipose-derived FFA, several factors contribute to hepatic fat deposition: I) Increased fatty acid synthesis from ethanol-induced metabolism (increased NADH from ethanol metabolism induces fatty acid synthesis); II) Impaired fat transport out of the liver via reduced very-low-density lipoprotein (VLDL) secretion; III) Decreased fatty acid oxidation (Rasineni and Casey, 2012; Osna et al., 2022; Yan et al., 2023). The resulting accumulation of fat in hepatocytes makes the liver susceptible to inflammatory mediators and/or toxic agents, leading to progressive injury, which progresses to alcoholic steatohepatitis (ASH), fibrosis, cirrhosis, and cancer (; Mackowiak et al., 2024). The only effective therapeutic strategies currently available for ALD are alcohol abstinence or liver transplantation (; ; ; ). Any molecule with dual-pronged effects at the central and peripheral organs controlling alcohol craving and alcohol-associated metabolic dysregulation could be a promising therapeutic target to treat alcohol use disorder (AUD) and ALD.
3.3 Metabolic dysfunction and alcohol-associated liver disease (MetALD)
The newly recognized subcategory, MetALD, highlights the potent synergy between toxic and metabolic insults. In this recently classified subcategory of liver disease, the co-existence of diet-induced obesity (a metabolic factor) and moderate to high amounts of alcohol consumption creates a double-hit injury. This combination synergistically increases disease progression and HCC risk significantly compared to obesity or alcohol alone (; Marek and Malhi, 2024; ; Schonfeld et al., 2021).
While the individual pathologies of MASLD and ALD are well-established, the specific pathophysiological mechanisms for MetALD development remain under active investigation and are currently considered hypothetical models that require further clinical validation. However, it is proposed that ethanol metabolism directly impairs the hepatic redox state by increasing the NADH/NAD+ ratio. This increased NADH promotes de novo lipogenesis while simultaneously decreasing fatty acid oxidation (Rasineni and Casey, 2012). Beyond the liver, alcohol administration disturbs lipid homeostasis within adipose tissue, triggering a pathological flux of FFA from peripheral fat depots to the liver (Zhong et al., 2012; Wei et al., 2013; ; Rasineni et al., 2019a; ; Rasineni et al., 2019b). This alcohol-induced steatosis is further compounded by the systemic insulin resistance from obesity, which independently drives an influx of FFA to the liver. Furthermore, the induction of CYP2E1 during chronic alcohol consumption generates massive amounts of ROS, which likely accelerates mitochondrial dysfunction and ER stress, and inflammatory signaling.
This detrimental progression of liver diseases is often driven by a behavioral cycle involving an increased desire, cravings, and high-calorie food intake during and after alcohol drinking episodes and vice versa. Notably, both MASLD and ALD exhibit similar histology and share some pathological mechanisms, reinforcing the idea that altered metabolic homeostasis in the liver and adipose tissue is the final common pathway driving liver injury (Kalligeros et al.; ; Marek and Malhi, 2024; ; ). However, further studies are warranted to fully delineate the distinct pathophysiology of MetALD development, which is driven by both alcohol and metabolic dysfunction.
3.4 Chronic viral hepatitis (HBV and HCV)
While HBV and HCV are primarily known as infectious diseases, their persistent presence induces profound metabolic reprogramming specifically within the host liver cells (hepatocytes), which contributes significantly to the risk of advanced liver disease and HCC (Wang and Zhang, 2023; Suhail et al., 2022; R et al., 2022). This viral-induced dysmetabolism creates a powerful synergy with the underlying drivers of SLD (Schinzari et al., 2015).
HCV infection is strongly associated with systemic insulin resistance and T2DM (). Critically, the virus achieves this by interfering with crucial host signaling pathways within the liver. Specifically, the HCV core protein is known to induce the degradation of insulin receptor substrate (IRS-1 and IRS-2) components, which are vital for proper insulin signaling in hepatocytes (). This interference promotes IR at the cellular level, intensifying the burden of hyperinsulinemia and hyperglycemia on the liver (; Pazienza et al., 2007).
Furthermore, HCV directly alters hepatic lipid metabolism in a way that mimics and exacerbates hepatic steatosis. The virus promotes the formation and accumulation of lipid droplets (LDs) within hepatocytes, a process essential for its own life cycle, including viral replication and assembly (; Perlemuter et al., 2002). The resulting high levels of intrahepatic fat deposition, coupled with the persistent IR, accelerate the chronic inflammatory and fibrotic processes characteristic of advanced liver disease (Salmon et al., 2012).
HBV, a DNA virus, has also been shown to modulate host metabolic pathways to support its life cycle, with primary effects observed in the liver. Viral proteins, particularly the hepatitis B virus X protein (HBx), act as an important positive regulator for gluconeogenesis (Shin et al., 2011). Further, HBx interacts with cellular machinery to alter lipid homeostasis in the hepatocyte (Yang et al., 2008). HBx can influence the activity of metabolic transcription factors, such as sterol regulatory element-binding proteins (SREBPs), which are key regulators of de novo lipogenesis (). This modulation leads to observable steatosis in the liver of some chronic carriers.
Thus, for viral etiologies, the virus acts as the initial trigger, but the resulting metabolic dysregulation and chronic inflammatory state which overlaps significantly with the pathophysiology of MASLD are focused on and ultimately destroy the liver’s tissue architecture, creating the sustained carcinogenic environment (Wang and Zhang, 2023; Suhail et al., 2022; R et al., 2022; Schinzari et al., 2015). Critically, even after successful viral eradication (e.g., sustained virologic response in HCV), residual metabolic damage within the liver can persist, leaving patients with a continued, metabolically-driven risk for HCC (Przybyszewski and Chung, 2023).
4 Current therapeutic landscape and unmet need
While resmetirom (a THR-β agonist) has recently gained FDA approval for the treatment of MASH (in patients with fibrosis F2-F3), marking the first-ever pharmacological agent for this condition (), there remains no single FDA-approved drug that effectively prevents or reverses the progression of advanced SLD to HCC. The therapeutic approach for HCC remains focused on curative treatments for early stages (resection, ablation, transplantation) or palliative systemic therapies for advanced disease (tyrosine kinase inhibitors [TKIs] and VEGF inhibitors) and immunotherapies (i.e., programmed death 1 [PD-1]/programmed cell death-ligand 1 [PD-L1] inhibitors and anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] antibodies) (Sadagopan et al., 2024; ).
Management of the underlying SLDs typically revolves around etiology-specific interventions: lifestyle modifications (diet, exercise, and weight loss) are the cornerstone for MASLD/MASH; complete alcohol cessation (abstinence) is critical for ALD/MetALD; and antivirals are used to suppress viral load in chronic hepatitis (; Sengupta and Mellinger, 2024). However, while lifestyle modification (such as calorie restriction and alcohol abstinence) represents the therapeutic gold standard for MASLD and ALD, achieving and, more importantly, sustaining these intensive behavioral changes over the long term is a significant clinical challenge (; Rajewski et al., 2025). This difficulty in maintaining persistent intervention means that the underlying metabolic dysfunction often continues as the primary driver of advanced liver disease, even in patients who have achieved viral cure or who struggle with these rigorous modifications. This gap defines a critical therapeutic void. There is an urgent need for a pharmacological agent that can specifically and safely correct the shared metabolic pathology, ideally by acting at both central (e.g., controlling appetite and cravings) and peripheral (e.g., improving insulin sensitivity, reducing hepatic fat and inflammation) levels to support and enhance existing behavioral strategies, thereby lowering the risk of advanced liver disease development across metabolic and alcoholic etiologies.
5 GLP-1 receptor agonists: a multi-functional therapeutic targeting metabolic dysfunction
Glucagon-like peptide-1 (GLP-1), a multifaceted hormone expressed primarily in the intestines and pancreas, mediates physiological and behavioral properties through its receptor, GLP-1 receptors (GLP-1R). The GLP-1R is widely expressed in both central and peripheral tissues, including the brain, heart, and kidney. Importantly, several studies have reported GLP-1R expression on both hepatocytes (liver cells) and adipocytes (fat cells) (; Zhang et al., 2025; Mahalingam et al., 2023; Vendrell et al., 2011; Muller et al., 2019). However, this remains an area of active debate within the field; while some studies report direct hepatocyte GLP-1R signaling (Shantaram et al., 2025; ; Sharma et al., 2011; ; ; Wang et al., 2015), others suggest that many hepatic benefits may be indirect, mediated via weight loss, improved insulin sensitivity, and adipose-liver crosstalk (). Regardless of the specific signaling site, the therapeutic potential of GLP-1 remains significant. Given the rapid degradation of the natural GLP-1 hormone (with a half-life of only ∼2 min), with therapeutic potential motivated the development of long-acting GLP-1 receptor agonists (GLP-1 RAs). These synthetic analogs possess significantly long half-life and are now used clinically. Originally developed as glucose-lowering agents for T2DM (; ), GLP-1 RAs function as incretin mimetics, stimulating insulin release by pancreatic β-cells in a glucose-dependent manner while suppressing glucagon secretion from α-cells (Figure 1).
FIGURE 1
The mechanism of GLP-1 RAs, however, is now understood to extend far beyond glucose control, offering powerful dual central and peripheral action. Centrally, they manage appetite and cravings by modulating the reward circuitry in the brain, while peripherally, they correct systemic metabolism and reduce hepatic fat accumulation (; Skibicka, 2013; Shantaram et al., 2025; Weghuber et al., 2022; ). This critical dual action is reinforced by data showing that GLP-1R agonists reduce the intake of both high-calorie food and alcohol, which are key drivers of SLDs (; ; ; Weghuber et al., 2022; ). This multi-functional activity positions GLP-1Rs as a class of medications that target the fundamental metabolic dysregulation driving SLD and the progression to advanced liver injury, thus establishing their role as a leading therapeutic strategy for managing the risk of advanced liver disease and HCC.
Importantly, this mechanistic framework is increasingly supported by large-scale clinical outcome data. Studies involving large patient cohorts demonstrate that GLP-1RA use is associated with a reduced all-cause mortality and decreased progression to decompensated cirrhosis among patients with MASLD/MASH. Furthermore, non-users of GLP-1RAs exhibited more than a twofold higher risk of all-cause mortality compared with GLP-1RA users (; ).
5.1 Systemic and hepatic efficacy: Correcting metabolic derangements and steatosis
As depicted in Figure 1, GLP-1 RAs are highly effective at correcting the core metabolic derangements seen in MASLD/T2DM. Their systemic efficacy is initiated by achieving significant and sustained weight loss and improved insulin sensitivity. This is accomplished centrally by reducing appetite and peripherally by delaying gastric emptying and enhancing glucose-dependent insulin secretion. These potent systemic actions lead to a reduction in visceral adiposity and dramatically improve systemic metabolic control (Weghuber et al., 2022; ; ; Mocciaro et al., 2025).
These systemic improvements translate directly to the liver, where GLP-1 RAs provide potent hepatic benefits that extend beyond simple weight loss (Summary of studies evaluating the role of GLP-1RAs in SLDs presented in Table 1). Mechanistically, they directly promote hepatic glucose metabolism and reduce fat accumulation. They reduce de novo lipogenesis by inhibiting transcription factor sterol regulatory element-binding protein 1c (SREBP-1c), which is a master regulator of fatty acid synthesis (Shantaram et al., 2025; ). Concurrently, they promote fatty acid β-oxidation by increasing peroxisome proliferator-activated receptor alpha (PPARα), a transcriptional factor regulating genes involved in mitochondrial and peroxisomal fatty acid catabolism (). This crucial dual action of reducing synthesis and increasing catabolism effectively decreases intrahepatic triglyceride content. Furthermore, by improving overall insulin sensitivity, GLP-1RAs decrease the toxic influx of free fatty acids from adipose tissue to the liver, thereby mitigating hepatic lipotoxicity (Wang et al., 2017). Beyond lipid metabolism, the GLP-1 RAs also shown critical anti-inflammatory and antioxidant effects, collectively positioning these GLP-1 RAs as a leading pharmacotherapy for MASLD (; Pasta et al., 2025; Wang L. et al., 2024; Wei et al., 2025). Clinically, this potent effect is demonstrated by agents like semaglutide, which, in phase 2 trials, achieved MASH resolution without worsening fibrosis in a significant percentage of patients (; Newsome et al., 2021; Petta et al., 2025; Sanyal et al., 2025; ; ).
TABLE 1
| GLP-1RAs | Animal model/clinical study | Biological actions | Level of evidence | References |
|---|---|---|---|---|
| Exenatide (Ex-4) | Clinical trial | Exenatide decreased alcohol intake in overweight alcohol use disorder (AUD) patients | Clinical | |
| Dulaglutide | Clinical study | Dulaglutide treatment decreased alcohol intake in smoking AUD patients | Clinical | Probst et al. (2023) |
| Semaglutide and tirzepatide | Clinical study | Semaglutide lowered binge drinking, alcohol use disorder identification test (AUDIT) scores, and self-reported alcohol intake in overweight individuals with high alcohol intake | Clinical | (Quddos et al., 2023) |
| Exendin-4 | Lieber-DeCarli ethanol-diet fed rat | Exendin-4 reduces hepatic steatosis in Lieber-DeCarli ethanol-diet fed animals by improving insulin signaling and fat metabolism | Clinical | Mahalingam et al. (2023) |
| GLP-1RAs | Clinical study | GLP-1R agonist treatment reduces the desire to consume alcohol, interest in alcohol, and alcohol consumption in patients treated for obesity or type 2 diabetes | Clinical | |
| GLP-1RAs | Clinical and experimental animal study | GLP-1RAs reduce alcohol consumption | Clinical | |
| Semaglutide | Clinical trial | Low-dose semaglutide over 9 weeks of treatment can reduce alcohol craving and some drinking outcomes | Clinical | |
| Liraglutide | HepG2 cells | HepG2 cells decreased proliferation after liraglutide treatment without altering oxidative stress levels. Liraglutide was able to induce autophagy and senescence through the increase of TGF-β1, which possibly explains the growth decrease | In vitro | |
| Exenatide (Ex-4) | Obese DEN-treated mice | Ex-4 significantly improved obesity-induced hyperglycemia and hyperlipidemia and reduced HCC multiplicity in obese DEN-treated mice, in which suppressed proliferation and induced apoptosis were confined to tumor cells | In vivo | Zhou et al. (2017) |
| Exenatide (Ex-4) | HepG2 cells | Exenatide has a potent anti-proliferative activity via mTOR modulation using HepG2 cells | In vitro | |
| Liraglutide | Mouse | Liraglutide prevented the progression of hepatocellular carcinoma in a mouse model of Nonalcoholic Steatohepatitis | In vivo | |
| Liraglutide | Mouse | Liraglutide activates natural killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma | In vivo | |
| Semaglutide | GAN-DIO‐NASH mice | Semaglutide prevents NASH-driven HCC progression in a metabolic translational preclinical model | In vivo | Mollerhoj et al. (2022) |
| Liraglutide | HFD mice | Liraglutide ameliorates hepatic steatosis via retinoic acid receptor-related orphan receptor α-mediated autophagy pathway | In vivo | Yu et al. (2023) |
| Semaglutide | GAN diet-induced obese | Semaglutide improves both NASH and tumor burden in GAN DIO-NASH-HCC mice, highlighting the suitability of this preclinical model for profiling novel drug therapies targeting NASH-HCC. | In vivo | |
| Semaglutide | HFD-induced obese mice | Semaglutide treatment decelerates the progression of liver cancer by inducing the expression of ITGAV, LAMC1, FABP5, and LPL in the adipose tissue of obese mice | In vivo | |
| GLP-1R agonists | Meta-analysis | GLP-1 RAs provide protective benefits against HCC in T2DM patients compared to insulin or no GLP-1 RAs, but not significantly over other antidiabetic medications | Meta-analysis | Shabil et al. (2024) |
| GLP-1R agonists | Meta-analysis | GLP-1RAs were associated with significant risk reductions in long-term adverse liver outcomes, including hepatic decompensation, portal hypertension, HCC, and LT, in MASLD cirrhosis patients with type 2 diabetes | Meta-analysis | |
| Semaglutide | MASH or Advanced liver fibrosis | Semaglutide at a dose of 2.4 mg improved liver histologic results in patients with MASH or advanced liver fibrosis | Clinical | Sanyal et al. (2025) |
| GLP-1R agonists | Meta-analysis | Meta-analysis provides evidence for the effectiveness of GLP-1 receptor agonists in managing MAFLD, with dual GLP-1/GIP agonists demonstrating superior hepatic benefits | Meta-analysis | Tamilwanan et al. (2025) |
Therapeutic actions of GLP-1 receptor agonists in liver disease: summary of experimental and clinical findings.
Abbreviations used in the table: HepG2: human liver cancer cell line; TGF-β1: transforming growth factor beta 1; HCC: hepatocellular carcinoma; DEN: diethylnitrosamine; mTOR: mechanistic target of rapamycin; IL-6: interleukin-6; STAT3: signal transducer and activator of transcription 3; NASH: nonalcoholic steatohepatitis; GAN DIO: gubra amylin NASH, diet-induced obese; LAMC1: laminin subunit gamma 1; FABP5:fatty acid binding protein 5; LPL: lipoprotein lipase; GLP-1, RA: glucagon-like peptide-1, receptor agonist; LT: liver transplant; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; MAFLD: metabolic associated fatty liver disease; GIP: glucose-dependent insulinotropic polypeptide; AUD: alcohol use disorder; AUDIT: alcohol use disorders identification test.
Furthermore, liraglutide and semaglutide have both demonstrated anti-fibrotic effects and their use in preclinical models prevents NASH-driven HCC progression (Sanyal et al., 2025; Mantovani et al., 2021). Beyond MASLD, emerging preclinical evidence highlights the therapeutic potential of GLP-1 RAs in ALD and MetALD (Singal and Leggio, 2025). Specifically, our published data confirms that exendin-4, significantly improves ALD pathology by reducing hepatic steatosis, inflammation, and oxidative stress in experimental rats (Mahalingam et al., 2023). In addition to our study, a recent clinical cohort study indicated that GLP-1 RA use was associated with significantly fewer liver-related outcomes. This includes reduced rates of acute decompensated liver failure and alcoholic hepatitis, although, notably, no significant difference was observed in the progression to cirrhosis within the study period (Wickramarachchi et al., 2025).
The central action of GLP-1 receptor agonists is supported by evidence showing that exenatide and semaglutide reduce the intake of high-calorie foods and alcohol, as well as relapse-like drinking in rodent models. These critical effects are mediated through GLP-1R signaling within the mesolimbic reward system, which directly targets key drivers of AUD, ALD, and MetALD. Preclinical and clinical studies have demonstrated that GLP-1RAs reduce both alcohol craving and intake, confirming the direct neurobiological pathway targeted by this drug class (; ; ; ; ; Patel et al., 2025). This universality even extends to viral hepatitis, as liraglutide has been shown in vitro to directly inhibit HCV replication through an AMPK-dependent mechanism (), reinforcing the drug class’s broad impact on metabolic health critical for diverse liver pathologies. This combined systemic, direct hepatic, anti-addictive, and even anti-viral action establishes GLP-1RAs as a powerful, novel approach to reduce the cumulative toxic insults driving SLD progression across multiple etiologies.
5.2 Anti-inflammatory and direct tumor-suppressive signaling
GLP-1 receptor agonists exert direct modulatory effects on some molecular pathways implicated in HCC initiation and progression, effects that may occur independently of reducing visceral adipose tissue and pro-inflammatory adipokine release from adipose tissue. Recognizing that chronic inflammation is a major driver of SLD progression and hepatocarcinogenesis, GLP-1 RAs demonstrate potent anti-inflammatory and tumor-suppressive actions (Que et al., 2019; Wan and Sun, 2019; ; Zhao et al., 2014). The core tumor-suppressive mechanism involves activating AMP-activated protein kinase (AMPK), a key cellular energy sensor. AMPK activation subsequently inhibits the mTORC pathway (a major regulator of cell growth and proliferation) and promotes cell cycle arrest by stabilizing p53 and the p21/p27 inhibitors (; ). This direct molecular targeting underpins their utility as specific anti-cancer agents.
Preclinical studies validate these direct anti-tumor effects across different agents: Liraglutide, for instance, demonstrates potent anti-cancer activity by suppressing HCC progression in mouse models, crucially exhibiting an anti-inflammatory effect by inhibiting the IL-6/STAT3 signaling pathway (; ). This action enhances antitumor activity via NK-mediated cytotoxicity, while liraglutide also induces autophagy and senescence in HepG2 cells via TGF-β modulation (; ). Similarly, exenatide-4 inhibits hepatocarcinogenesis independent of obesity and MASH resolution, acting through the cAMP-PKA-EGFR-STAT3 axis and mTOR modulation to suppress proliferation and reduce HCC multiplicity (Zhou et al., 2017). Furthermore, semaglutide prevents MASLD/MASH-driven HCC progression in metabolic preclinical models, partly by correcting adipokine imbalances (low adiponectin, high leptin) associated with insulin resistance, which removes a key chronic inflammatory and pro-oncogenic signal linked to the disease ().
It is important to note that most of the evidence supporting the anti-tumor efficacy of GLP-1 RAs is derived from preclinical studies, including in vitro studies and animal experiments demonstrating reduced proliferation of the cancer cells, enhanced apoptosis, and modulation of oncogenic signaling pathways (). In humans, current data remain largely associative, based on observational and epidemiological studies reporting lower HCC incidence among GLP-1 RA users compared to placebo. However, there are no randomized controlled trials with HCC incidence as a primary endpoint, and the observed associations may be influenced by confounding factors such as weight reduction, improved glycemic control, and concomitant use of statins or other hepatoprotective agents. These limitations underscore the need for prospective, well-designed clinical trials to establish causality and clarify the direct role of GLP-1 RAs in HCC prevention.
These systemic and direct molecular effects, particularly the potent anti-inflammatory actions and metabolic correction, are highly relevant to mitigating the progression of both ALD and MetALD. By resolving the underlying steatosis and reducing the chronic inflammatory burden, GLP-1 RAs reinforce their potential as powerful anticancer agents across the full spectrum of SLD. However, further preclinical studies, especially those focusing on ALD and MetALD models, and prospective clinical trials are necessary to fully translate these promising anticancer benefits to human patients.
5.3 Tolerability and safety profile of GLP-1 receptor agonists
GLP-1 receptor agonists are generally well tolerated; however, gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are the most frequently reported, particularly during the initial treatment phase (Wilding et al., 2021; Wharton et al., 2022; ; ). These symptoms are typically transient but may lead to treatment discontinuation in approximately 5%–10% of patients. Less frequent but clinically relevant risks include pancreatitis and gallbladder disease, such as cholelithiasis and cholecystitis (Sodhi et al., 2023; ). Although a causal association with acute pancreatitis remains debated, observational studies suggest a higher incidence compared with placebo (Nieto et al., 2025; Storgaard et al., 2017; Pinto et al., 2019). GLP-1 RAs also delay gastric emptying, which contributes to satiety but may exacerbate symptoms in patients with pre-existing gastroparesis (; ).
Additionally, weight loss with GLP-1 RAs is accompanied by reductions in lean mass, with skeletal muscle accounting for approximately 15%–40% of total weight loss (Pandey et al., 2024; Sargeant et al., 2019), raising significant concerns regarding sarcopenia, particularly in older or frail individuals with cirrhosis. Caution is advised in patients with a history of severe gastrointestinal disorders or pancreatitis. While these adverse effects do not typically outweigh the substantial metabolic benefits, they may limit use in specific patient populations, necessitating careful dose titration and clinical monitoring. Also, side effects for GLP-1RAs in liver disease patients often include gastrointestinal issues, which can be managed with lower initial doses.
6 Conclusion and future directions
The data strongly supports that SLD, is fueled by common pathways of altered metabolism and chronic inflammation, which are the central precipitating factors for HCC development across MASLD, ALD, and to some extent, chronic viral etiologies. Given this unifying pathophysiology, GLP-1 RAs, with their powerful ability to act both centrally (controlling appetite and cravings) and peripherally (correcting systemic metabolic dysfunction, resolving hepatic steatosis and inflammation), to exert direct anti-carcinogenic effects, represent a truly multi-functional therapeutic tool. Their ability to simultaneously address metabolic risk factors, inflammation, and cellular proliferation positions them as one of the most promising drug classes for interrupting SLD progression (Figure 2).
FIGURE 2
The encouraging efficacy of GLP-1 RAs in reversing MASH histology in clinical trials and reducing HCC risk in epidemiological studies provides a powerful mandate for further investigation. However, the next phase of translational research must now broaden its scope. Specifically, future work should prioritize conducting specific animal studies to validate the hypothesized anti-fibrotic and anti-cancer effects of GLP-1 RAs in ALD and MetALD models.
Crucially, more clinical studies are required to definitively establish the efficacy and safety of GLP-1 RAs for the treatment of ALD and MetALD. These trials must move beyond MASLD and include populations with significant alcohol exposure and mixed etiologies. Furthermore, research is critical to investigate the impact of GLP-1 RAs on HCC risk in patients with significant metabolic risk factors, including those who have achieved viral suppression from chronic viral hepatitis. Ultimately, the definitive role of GLP-1 RAs as an anticancer agent pivot on launching large-scale, randomized controlled trials focused explicitly on the primary prevention of HCC in high-risk patients with advanced SLD of all major etiologies.
Statements
Author contributions
SM: Writing – original draft. KK: Writing – review and editing. CC: Writing – review and editing. KR: Writing – review and editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. Authors were supported by the National Institutes of Health/NIAAA funding R01AA028504 (KR); P50AA030407-5131 (KKK). Also supported by Department of Veterans Affairs, Veterans Health administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Review grant I01BX006064 (KKK).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors KK, KR declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AciernoC.BarlettaF.CaturanoA.NevolaR.SassoF. C.AdinolfiL. E.et al (2025). Alcohol consumption and liver metabolism in the era of MASLD: integrating nutritional and pathophysiological insights. Nutrients17 (13), 2229. 10.3390/nu17132229
2
AddoloratoG.MirijelloA.LeggioL.FerrulliA.LandolfiR. (2013). Management of alcohol dependence in patients with liver disease. CNS Drugs27 (4), 287–299. 10.1007/s40263-013-0043-4
3
AdekunleA. D.AdejumoA.SingalA. K. (2023). Therapeutic targets in alcohol-associated liver disease: progress and challenges. Ther. Adv. Gastroenterol.16, 17562848231170946. 10.1177/17562848231170946
4
ArmandiA.BugianesiE. (2024). Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. Eur. J. Intern Med.122, 20–27. 10.1016/j.ejim.2024.01.005
5
ArmstrongM. J.HullD.GuoK.BartonD.HazlehurstJ. M.GathercoleL. L.et al (2016). Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol.64 (2), 399–408. 10.1016/j.jhep.2015.08.038
6
ArvanitakisK.KoufakisT.KotsaK.GermanidisG. (2022). How far beyond diabetes can the benefits of glucagon-like Peptide-1 receptor agonists go? A review of the evidence on their effects on hepatocellular carcinoma. Cancers (Basel)14 (19), 4651. 10.3390/cancers14194651
7
BabutaM.MorelC.de Carvalho RibeiroM.DattaA. A.CalendaC.CopelandC.et al (2024). A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis. Hepatol. Commun.8 (7), e0450. 10.1097/HC9.0000000000000450
8
BodenG.SheP.MozzoliM.CheungP.GumireddyK.ReddyP.et al (2005). Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes54 (12), 3458–3465. 10.2337/diabetes.54.12.3458
9
BoseS. K.ShrivastavaS.MeyerK.RayR. B.RayR. (2012). Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J. Virol.86 (11), 6315–6322. 10.1128/JVI.00050-12
10
BrayF.LaversanneM.SungH.FerlayJ.SiegelR. L.SoerjomataramI.et al (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.74 (3), 229–263. 10.3322/caac.21834
11
BremmerM. P.HendershotC. S. (2024). Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders. J. Stud. Alcohol Drugs85 (1), 5–11. 10.15288/jsad.23-00318
12
BruntonS. A.WyshamC. H. (2020). GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad. Med.132 (Suppl. 2), 3–14. 10.1080/00325481.2020.1798099
13
BuT.SunZ.PanY.DengX.YuanG. (2024). Glucagon-like Peptide-1: new regulator in lipid metabolism. Diabetes Metab. J.48 (3), 354–372. 10.4093/dmj.2023.0277
14
CaiY.XieS.XuL.ChenJ.CaiJ. (2025). Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications. Diabetol. Metab. Syndr.17 (1), 300. 10.1186/s13098-025-01870-x
15
ChangB.TianH.HuangA.ZhaiX.WangQ.HanL.et al (2024). Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases. eGastroenterology2 (1), e100036. 10.1136/egastro-2023-100036
16
ChenM. J.ChenY.LinJ. Q.HuR.LiuD.ChenJ. Y.et al (2024). Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease. Front. Nutr.11, 1421386. 10.3389/fnut.2024.1421386
17
ChenW. M.NgH. J.JaoA. T.WuS. Y.SoongR. S. (2025). GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score-matched population-based cohort study. Diabetes Res. Clin. Pract.227, 112407. 10.1016/j.diabres.2025.112407
18
Chen-LiawA. Y.HammelG.GomezG. (2017). Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells. Vitro Cell Dev. Biol. Anim.53 (8), 721–727. 10.1007/s11626-017-0181-y
19
ChoiJ.KimH.-s. (2025). Alcohol-associated liver disease and risk stratification for hepatocellular carcinoma: a comprehensive review. Curr. Hepatol. Rep.24 (1), 13. 10.1007/s11901-025-00684-9
20
ChuongV.FarokhniaM.KhomS.PinceC. L.ElvigS. K.VlkolinskyR.et al (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight8 (12), e170671. 10.1172/jci.insight.170671
21
CusiK. (2019). Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes. Hepatology69 (6), 2318–2322. 10.1002/hep.30670
22
CusiK.SattarN.Garcia-PerezL. E.PavoI.YuM.RobertsonK. E.et al (2018). Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet. Med.35 (10), 1434–1439. 10.1111/dme.13697
23
CusiK.AbdelmalekM. F.ApovianC. M.BalapattabiK.BannuruR. R.BarbD.et al (2025). Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association. Diabetes Care48 (7), 1057–1082. 10.2337/dci24-0094
24
da Silva LimaN.CabaleiroA.NovoaE.RiobelloC.KnerrP. J.HeY.et al (2024). GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells. Cell Mol. Life Sci.81 (1), 468. 10.1007/s00018-024-05507-6
25
DanpanichkulP.SuparanK.DiazL. A.FallonM. B.ChenV. L.NamsathimaphornK.et al (2025). The rising global burden of MASLD and other metabolic diseases (2000-2021). United Eur. Gastroenterol. J.13 (7), 1141–1154. 10.1002/ueg2.70072
26
DingX.SaxenaN. K.LinS.GuptaN. A.AnaniaF. A. (2006). Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology43 (1), 173–181. 10.1002/hep.21006
27
DingZ.WangL.SunJ.ZhengL.TangY.TangH. (2025). Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances. Front. Oncol.15, 1526206. 10.3389/fonc.2025.1526206
28
DuaA.KumariR.SinghM.KumarR.PradeepS.OjesinaA. I.et al (2025). Metabolic dysfunction-associated steatotic liver disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes. Front. Med. (Lausanne)12, 1618275. 10.3389/fmed.2025.1618275
29
El-ZayadiA. R.AnisM. (2012). Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J. Gastroenterol.18 (3), 212–224. 10.3748/wjg.v18.i3.212
30
ElsaidM. I.LiN.FirkinsS. A.RustgiV. K.PaskettE. D.AcharyaC.et al (2024). Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Aliment. Pharmacol. Ther.59 (9), 1096–1110. 10.1111/apt.17925
31
FarokhniaM.TazareJ.PinceC. L.BrunsNtGrayJ. C.Lo ReV.3rdet al (2025). Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J. Clin. Invest.135 (9), e188314. 10.1172/JCI188314
32
FengG.TargherG.ByrneC. D.YilmazY.Wai-Sun WongV.Adithya LesmanaC. R.et al (2025). Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep.7 (3), 101271. 10.1016/j.jhepr.2024.101271
33
GalassoL.CerritoL.MaccauroV.TermiteF.MigniniI.EspostoG.et al (2024). Inflammatory response in the pathogenesis and treatment of hepatocellular carcinoma: a double-edged weapon. Int. J. Mol. Sci.25 (13), 7191. 10.3390/ijms25137191
34
GaoB.LuY.LaiX.XuX.GouS.YangZ.et al (2025). Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications. Front. Immunol.16, 1592837. 10.3389/fimmu.2025.1592837
35
GargS.ZeinN. N. (2025). Emerging trends in MAFLD and MASH. Diabetes Technol. Ther.27 (S1), S227–S237. 10.1089/dia.2025.8818.sg
36
GhusnW.HurtadoM. D. (2024). Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes. Pillars12, 100127. 10.1016/j.obpill.2024.100127
37
GinesP.Serra-BurrielM.KamathP. S. (2025). Metabolic dysfunction-associated steatotic liver disease-the new epidemic of chronic liver disease. JAMA Netw. Open8 (6), e2516381. 10.1001/jamanetworkopen.2025.16381
38
GoldbergD.DitahI. C.SaeianK.LalehzariM.AronsohnA.GorospeE. C.et al (2017). Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology152 (5), 1090–9 e1. 10.1053/j.gastro.2017.01.003
39
GordanJ. D.KennedyE. B.Abou-AlfaG. K.BealE.FinnR. S.GadeT. P.et al (2024). Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J. Clin. Oncol.42 (15), 1830–1850. 10.1200/JCO.23.02745
40
Gratacos-GinesJ.ArinoS.Sancho-BruP.BatallerR.PoseE. (2025). MetALD: clinical aspects, pathophysiology and treatment. JHEP Rep.7 (2), 101250. 10.1016/j.jhepr.2024.101250
41
GuptaN. A.MellsJ.DunhamR. M.GrakouiA.HandyJ.SaxenaN. K.et al (2010). Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology51 (5), 1584–1592. 10.1002/hep.23569
42
GuptaN. A.KolachalaV. L.JiangR.AbramowskyC.RomeroR.FifadaraN.et al (2012). The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am. J. Pathol.181 (5), 1693–1701. 10.1016/j.ajpath.2012.07.015
43
HailemichaelD.RenataF.DavidH.FranciscoI.DanielC.Luis AntonioD.et al (2024). Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease. Metabolism Target Organ Damage4 (3), 25. 10.20517/mtod.2024.30
44
HajjouM.NorelR.CarverR.MarionP.CullenJ.RoglerL. E.et al (2005). cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J. Med. Virol.77 (1), 57–65. 10.1002/jmv.20427
45
HansenH. H.PorsS.AndersenM. W.VybergM.Nohr-MeldgaardJ.NielsenM. H.et al (2023). Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Sci. Rep.13 (1), 23056. 10.1038/s41598-023-50328-5
46
HardieD. G. (2013). AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes62 (7), 2164–2172. 10.2337/db13-0368
47
HardieD. G.RossF. A.HawleyS. A. (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol.13 (4), 251–262. 10.1038/nrm3311
48
HarrisK. (2025). An unmet need in MetALD. Hepatology81 (2), 385–386. 10.1097/HEP.0000000000001168
49
HavranekB.LohR.TorreB.RedfieldR.Halegoua-DeMarzioD. (2025). Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci. Rep.15 (1), 4947. 10.1038/s41598-025-89408-z
50
HeL.WangJ.PingF.YangN.HuangJ.LiY.et al (2022). Association of glucagon-like Peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med.182 (5), 513–519. 10.1001/jamainternmed.2022.0338
51
HeX.ZhaoW.LiP.ZhangY.LiG.SuH.et al (2024a). Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus. Front. Pharmacol.15, 1483792. 10.3389/fphar.2024.1483792
52
HeK. J.WangH.XuJ.GongG.LiuX.GuanH. (2024b). Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021. Front. Endocrinol. (Lausanne)15, 1501690. 10.3389/fendo.2024.1501690
53
HendershotC. S.BremmerM. P.PaladinoM. B.KostantinisG.GilmoreT. A.SullivanN. R.et al (2025). Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry82 (4), 395–405. 10.1001/jamapsychiatry.2024.4789
54
HoG. J. K.TanF. X. N.SasikumarN. A.ThamE. K. J.KoD.KimD. H.et al (2025). High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis. Clin. Gastroenterol. Hepatol.23 (13), 2423–2432. 10.1016/j.cgh.2025.02.006
55
HosseinkhanN.NajafiL.JahangiriS.EmamiZ.KhamsehM. E. (2025). Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis. BMC Cancer25 (1), 875. 10.1186/s12885-025-14299-2
56
HuQ.ZhangL.TaoY.XieS.WangA.LuoC.et al (2025). Semaglutide ameliorates hepatocyte steatosis in a cell Co-Culture system by downregulating the IRE1alpha-XBP1-C/EBPalpha signaling pathway in macrophages. Pharmacology110 (1), 26–35. 10.1159/000540654
57
HuangM.ChenH.WangH.ZhangY.LiL.LanY.et al (2025). Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030. Intern Emerg. Med.20 (4), 1013–1024. 10.1007/s11739-025-03895-6
58
IsaacsS. D.FarrellyF. V.BrennanP. N. (2025). Role of anti-diabetic medications in the management of MASLD. Frontline Gastroenterol.16 (3), 239–249. 10.1136/flgastro-2024-102856
59
JallehR. J.PlummerM. P.MaratheC. S.UmapathysivamM. M.QuastD. R.RaynerC. K.et al (2024). Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J. Clin. Endocrinol. Metab.110 (1), 1–15. 10.1210/clinem/dgae719
60
JaraM.NorlinJ.KjaerM. S.AlmholtK.BendtsenK. M.BugianesiE.et al (2025). Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat. Med.31 (9), 3128–3140. 10.1038/s41591-025-03799-0
61
JastreboffA. M.AronneL. J.AhmadN. N.WhartonS.ConneryL.AlvesB.et al (2022). Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med.387 (3), 205–216. 10.1056/NEJMoa2206038
62
JeeY. M.LeeJ. Y.RyuT. (2025). Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: from steatosis to hepatocellular carcinoma. Biomedicines13 (5), 1260. 10.3390/biomedicines13051260
63
JerlhagE. (2025). GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder. Endocrinology166 (4), bqaf028. 10.1210/endocr/bqaf028
64
JonesL. A.BrierleyD. I. (2025). GLP-1 and the neurobiology of eating control: recent advances. Endocrinology166 (2), bqae167. 10.1210/endocr/bqae167
65
KalligerosM.VassilopoulosA.VassilopoulosS.VictorD. W.MylonakisE.NoureddinM. (2024). Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clin. Gastroenterol. Hepatol.22 (6), 1330–2 e4. 10.1016/j.cgh.2023.11.003
66
KangL.SebastianB. M.PritchardM. T.PrattB. T.PrevisS. F.NagyL. E. (2007). Chronic ethanol-induced insulin resistance is associated with macrophage infiltration into adipose tissue and altered expression of adipocytokines. Alcohol Clin. Exp. Res.31 (9), 1581–1588. 10.1111/j.1530-0277.2007.00452.x
67
KanwalF.KramerJ. R.LiL.YangY. X.CaoY.YuX.et al (2024). GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med.184 (11), 1314–1323. 10.1001/jamainternmed.2024.4661
68
KarinM.KimJ. Y. (2025). MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. Mol. Oncol.19 (2), 275–294. 10.1002/1878-0261.13685
69
KawaguchiT.YoshidaT.HaradaM.HisamotoT.NagaoY.IdeT.et al (2004). Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol.165 (5), 1499–1508. 10.1016/S0002-9440(10)63408-6
70
KharbandaK. K.FarokhniaM.DeschaineS. L.BhargavaR.Rodriguez-FloresM.CaseyC. A.et al (2022). Role of the ghrelin system in alcohol use disorder and alcohol-associated liver disease: a narrative review. Alcohol Clin. Exp. Res.46 (12), 2149–2159. 10.1111/acer.14967
71
KimK. H.HongS. P.KimK.ParkM. J.KimK. J.CheongJ. (2007). HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem. Biophys. Res. Commun.355 (4), 883–888. 10.1016/j.bbrc.2007.02.044
72
KlausenM. K.JensenM. E.MollerM.Le DousN.JensenA. O.ZeemanV. A.et al (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight7 (19), e159863. 10.1172/jci.insight.159863
73
KojimaM.TakahashiH.KuwashiroT.TanakaK.MoriH.OzakiI.et al (2020). Glucagon-like Peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int. J. Mol. Sci.21 (16), 5722. 10.3390/ijms21165722
74
KrauseG. C.LimaK. G.DiasH. B.da SilvaE. F. G.HauteG. V.BassoB. S.et al (2017). Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells. Eur. J. Pharmacol.809, 32–41. 10.1016/j.ejphar.2017.05.015
75
KrauseG. C.LimaK. G.LevorseV.HauteG. V.GassenR. B.GarciaM. C.et al (2019). Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells. EXCLI J.18, 540–548. 10.17179/excli2019-1415
76
LawitzE. J.FraessdorfM.NeffG. W.SchattenbergJ. M.NoureddinM.AlkhouriN.et al (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J. Hepatol.81 (5), 837–846. 10.1016/j.jhep.2024.06.003
77
Leal-LassalleH.Estévez-VázquezO.CuberoF. J.NevzorovaY. A. (2025). Metabolic and alcohol-associated liver disease (MetALD): a representation of duality. NPJ Gut Liver2 (1), 1. 10.1038/s44355-024-00014-8
78
LeeM. Y.ChenW. C.HsuW. H.ChenS. C.LeeJ. C. (2019). Liraglutide inhibits hepatitis C virus replication through an AMP activated protein kinase dependent mechanism. Int. J. Mol. Sci.20 (18), 4569. 10.3390/ijms20184569
79
LeithD.LinY. Y.BrennanP. (2024). Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a deadly synergy. TouchREV Endocrinol.20 (2), 5–9. 10.17925/EE.2024.20.2.2
80
LekoA. H.LeggioL. (2024). Barriers to alcohol use disorder treatment in patients with alcohol-associated liver disease. Clin. Liver Dis.28 (4), 779–791. 10.1016/j.cld.2024.06.012
81
LiY.YangP.YeJ.XuQ.WuJ.WangY. (2024). Updated mechanisms of MASLD pathogenesis. Lipids Health Dis.23 (1), 117. 10.1186/s12944-024-02108-x
82
LiuY.ChenS.ZhenR. (2024). Effect of semaglutide on high-fat-diet-induced liver cancer in Obese mice. J. Proteome Res.23 (2), 704–717. 10.1021/acs.jproteome.3c00498
83
LiuJ.YangF.GaoB.YangL.CaoY.ZhouY. (2025). Resmetirom, the first FDA-approved drug for MASH: from drug discovery and action mechanisms to clinical trials. Arch. Pharm. Res.48 (11–12), 1299–1313. 10.1007/s12272-025-01574
84
LuX.XuC.DongJ.ZuoS.ZhangH.JiangC.et al (2021). Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma. Transl. Oncol.14 (1), 100872. 10.1016/j.tranon.2020.100872
85
MaY.WangJ.XiaoW.FanX. (2024). A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions. Front. Med. (Lausanne)11, 1410668. 10.3389/fmed.2024.1410668
86
MackowiakB.FuY.MaccioniL.GaoB. (2024). Alcohol associated liver disease. J. Clin. Invest.134 (3), e176345. 10.1172/JCI176345
87
MahalingamS.BellamkondaR.ArumugamM. K.PerumalS. K.YoonJ.CaseyC.et al (2023). Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease. Biochem. Pharmacol.213, 115613. 10.1016/j.bcp.2023.115613
88
MantovaniA.PetraccaG.BeatriceG.CsermelyA.LonardoA.TargherG. (2021). Glucagon-like Peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites11 (2), 73. 10.3390/metabo11020073
89
MarekG. W.MalhiH. (2024). MetALD: does it require a different therapeutic option?Hepatology80 (6), 1424–1440. 10.1097/HEP.0000000000000935
90
MillerD. M.McCauleyK. F.Dunham-SnaryK. J. (2025). Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinol. Diabetes Metab.8 (6), e70132. 10.1002/edm2.70132
91
MocciaroG.CapodiciA.De AmicisR. (2025). GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction. BMJ Nutr. Prev. Health8 (1), e001206. 10.1136/bmjnph-2025-001206
92
MollerhojM. B.VeidalS. S.ThraneK. T.OroD.OvergaardA.SalinasC. G.et al (2022). Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. Clin. Transl. Sci.15 (5), 1167–1186. 10.1111/cts.13235
93
MullerT. D.FinanB.BloomS. R.D'AlessioD.DruckerD. J.FlattP. R.et al (2019). Glucagon-like peptide 1 (GLP-1). Mol. Metab.30, 72–130. 10.1016/j.molmet.2019.09.010
94
NakamuraT.MasudaA.NakanoD.AmanoK.SanoT.NakanoM.et al (2025). Pathogenic mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma. Cells14 (6), 428. 10.3390/cells14060428
95
NewsomeP. N.BuchholtzK.CusiK.LinderM.OkanoueT.RatziuV.et al (2021). A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med.384 (12), 1113–1124. 10.1056/NEJMoa2028395
96
NietoL. M.MartinezJ.NarvaezS. I.KoD.KimD. H.VegaK. J.et al (2025). Glucagon-like Peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type 2 diabetes who develop acute pancreatitis: a multicenter analysis. Am. J. Gastroenterol.121 (2), 424–431. 10.14309/ajg.0000000000003525
97
Ochoa-AllemantP.SerperM.WangR. X.TangH.GhandourB.KhanS.et al (2025). Waitlisting and liver transplantation for MetALD in the United States: an analysis of the UNOS national registry. Hepatology81 (2), 532–545. 10.1097/HEP.0000000000000914
98
OsnaN. A.RasineniK.GanesanM.DonohueT. M.Jr.KharbandaK. K. (2022). Pathogenesis of alcohol-associated liver disease. J. Clin. Exp. Hepatol.12 (6), 1492–1513. 10.1016/j.jceh.2022.05.004
99
PanC. W.AbboudY.ChitnisA.ZhangW.SingalA. K.WongR. J. (2025). Alcohol-associated liver disease mortality. JAMA Netw. Open8 (6), e2514857. 10.1001/jamanetworkopen.2025.14857
100
PandeyA.PatelK. V.SegarM. W.AyersC.LingeJ.LeinhardO. D.et al (2024). Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial. J. Cachexia Sarcopenia Muscle15 (3), 1072–1083. 10.1002/jcsm.13445
101
PastaA.FacciorussoA.Plaz TorresM. C.GianniniE. G.SaccoR. (2025). Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: a systematic review and META-analysis. Eur. J. Clin. Invest.55 (6), e70000. 10.1111/eci.70000
102
PatelR.MuellerM. (2025). Alcohol-associated liver disease. StatPearls. Treasure Isl. (FL).
103
PatelS.BlaneyH.NassarS.SingalA. K. (2025). GLP-1 receptor agonists and alcohol use disorder: a systematic review. Alcohol Alcohol61 (1), agaf069. 10.1093/alcalc/agaf069
104
PazienzaV.ClementS.PugnaleP.ConzelmanS.FotiM.MangiaA.et al (2007). The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology45 (5), 1164–1171. 10.1002/hep.21634
105
PerlemuterG.SabileA.LetteronP.VonaG.TopilcoA.ChretienY.et al (2002). Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J.16 (2), 185–194. 10.1096/fj.01-0396com
106
PettaS.KimK.TargherG.RomeoS.SookoianS.ZhengM. H.et al (2025). Focus on semaglutide 2.4 mg/week for the treatment of metabolic dysfunction-associated steatohepatitis. Liver Int.45 (11), e70407. 10.1111/liv.70407
107
PieraliceS.AmendolaraR.BernaV.ManganaroG.ZurruA.D'OnofrioL.et al (2025). The emerging role of anti-hyperglycemic agents for the management of metabolic dysfunction-associated steatotic liver disease. Diabetes Metab. Syndr. Obes.18, 2477–2491. 10.2147/DMSO.S528569
108
PintoL. C.FalcettaM. R.RadosD. V.LeitaoC. B.GrossJ. L. (2019). Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Sci. Rep.9 (1), 2375. 10.1038/s41598-019-38956-2
109
ProbstL.MonneratS.VogtD. R.LengsfeldS.BurkardT.MeienbergA.et al (2023). Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight8 (22), e170419. 10.1172/jci.insight.170419
110
PrzybyszewskiE. M.ChungR. T. (2023). Unmet needs in the post-direct-acting antiviral era: hepatocarcinogenesis after hepatitis C virus eradication. J. Infect. Dis.228 (Suppl. 3), S226–S231. 10.1093/infdis/jiac447
111
QuddosF.HubshmanZ.TeggeA.SaneD.MartiE.KablingerA. S.et al (2023). Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci. Rep.13 (1), 20998. 10.1038/s41598-023-48267-2
112
QueQ.GuoX.ZhanL.ChenS.ZhangZ.NiX.et al (2019). The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. J. Inflamm. (Lond).16, 13. 10.1186/s12950-019-0218-y
113
RizzoG. E. M.CabibboG.CraxiA. (2022). Hepatitis B virus-associated hepatocellular carcinoma. Viruses14 (5), 986. 10.3390/v14050986
114
RajewskiP.CiescinskiJ.RajewskiP.SuwalaS.RajewskaA.PotaszM. (2025). Dietary interventions and physical activity as crucial factors in the prevention and treatment of metabolic dysfunction-associated steatotic liver disease. Biomedicines13 (1), 217. 10.3390/biomedicines13010217
115
RamaiteF. T.NkadimengS. M. (2025). Targeting inflammatory pathways in hepatocellular carcinoma: recent developments. Discov. Oncol.16 (1), 1174. 10.1007/s12672-025-03035-8
116
RasineniK.CaseyC. A. (2012). Molecular mechanism of alcoholic fatty liver. Indian J. Pharmacol.44 (3), 299–303. 10.4103/0253-7613.96297
117
RasineniK.ThomesP. G.KubikJ. L.HarrisE. N.KharbandaK. K.CaseyC. A. (2019a). Chronic alcohol exposure alters circulating insulin and ghrelin levels: role of ghrelin in hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol.316 (4), G453–G461. 10.1152/ajpgi.00334.2018
118
RasineniK.KubikJ. L.CaseyC. A.KharbandaK. K. (2019b). Inhibition of ghrelin activity by receptor antagonist [d-Lys-3] GHRP-6 attenuates alcohol-induced hepatic steatosis by regulating hepatic lipid metabolism. Biomolecules9 (10), 517. 10.3390/biom9100517
119
RileyD. R.HydesT.HernadezG.ZhaoS. S.AlamU.CuthbertsonD. J. (2024). The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int.44 (10), 2538–2550. 10.1111/liv.16016
120
SadagopanN.HeA. R. (2024). Recent progress in systemic therapy for advanced hepatocellular carcinoma. Int. J. Mol. Sci.25 (2), 1259. 10.3390/ijms25021259
121
SalmonD.Bani-SadrF.LokoM. A.StitouH.GervaisA.DurantJ.et al (2012). Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J. Hepatol.56 (4), 862–868. 10.1016/j.jhep.2011.11.009
122
SanyalA. J.NewsomeP. N.KliersI.OstergaardL. H.LongM. T.KjaerM. S.et al (2025). Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med.392 (21), 2089–2099. 10.1056/NEJMoa2413258
123
SargeantJ. A.HensonJ.KingJ. A.YatesT.KhuntiK.DaviesM. J. (2019). A review of the effects of glucagon-like Peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol. Metab. Seoul.34 (3), 247–262. 10.3803/EnM.2019.34.3.247
124
SchinzariV.BarnabaV.PiconeseS. (2015). Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin. Microbiol. Infect.21 (11), 969–974. 10.1016/j.cmi.2015.06.026
125
SchonfeldM.O'NeilM.VillarM. T.ArtiguesA.AverillaJ.GunewardenaS.et al (2021). A Western diet with alcohol in drinking water recapitulates features of alcohol-associated liver disease in mice. Alcohol Clin. Exp. Res.45 (10), 1980–1993. 10.1111/acer.14700
126
SenguptaS.MellingerJ. L. (2024). Preventive behavioral interventions for patients with steatotic liver disease. Clin. Liver Dis. Hob.23 (1), e0202. 10.1097/CLD.0000000000000202
127
ShabilM.KhatibM. N.BallalS.BansalP.TomarB. S.AshrafA.et al (2024). Risk of hepatocellular carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis. BMC Endocr. Disord.24 (1), 246. 10.1186/s12902-024-01775-2
128
ShantaramD.RimaX. Y.BradleyD.LiuJ. Z.WrightV. P.AmariA.et al (2025). The GLP-1 receptor agonist dulaglutide attenuates hepatic steatosis in obesity via a weight-independent mechanism. Diabetes74 (9), 1512–1524. 10.2337/db24-0861
129
SharmaS.MellsJ. E.FuP. P.SaxenaN. K.AnaniaF. A. (2011). GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One6 (9), e25269. 10.1371/journal.pone.0025269
130
ShiY.TaherifardE.SaeedA.SaeedA. (2024). MASLD-related HCC: a comprehensive review of the trends, pathophysiology, tumor microenvironment, surveillance, and treatment options. Curr. Issues Mol. Biol.46 (6), 5965–5983. 10.3390/cimb46060356
131
ShinH. J.ParkY. H.KimS. U.MoonH. B.ParkD. S.HanY. H.et al (2011). Hepatitis B virus X protein regulates hepatic glucose homeostasis via activation of inducible nitric oxide synthase. J. Biol. Chem.286 (34), 29872–29881. 10.1074/jbc.M111.259978
132
SingalA. K.LeggioL. (2025). GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease. Lancet Gastroenterol. Hepatol.10 (8), 707–709. 10.1016/S2468-1253(25)00134-7
133
SkibickaK. P. (2013). The central GLP-1: implications for food and drug reward. Front. Neurosci.7, 181. 10.3389/fnins.2013.00181
134
SodhiM.RezaeianzadehR.KezouhA.EtminanM. (2023). Risk of gastrointestinal adverse events associated with glucagon-like Peptide-1 receptor agonists for weight loss. JAMA330 (18), 1795–1797. 10.1001/jama.2023.19574
135
StefanN.Yki-JarvinenH.Neuschwander-TetriB. A. (2025). Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol.13 (2), 134–148. 10.1016/S2213-8587(24)00318-8
136
StorgaardH.ColdF.GluudL. L.VilsbollT.KnopF. K. (2017). Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes. Metab.19 (6), 906–908. 10.1111/dom.12885
137
SuhailM.SohrabS. S.KamalM. A.AzharE. I. (2022). Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview. Front. Oncol.12, 913231. 10.3389/fonc.2022.913231
138
TamilwananS.AzizZ.RongL. Y.BitarA. N.ZarzourR. H. A.AlshehadeS. A. (2025). Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials. BMC Gastroenterol.25 (1), 765. 10.1186/s12876-025-04358-0
139
TantuM. T.FarhanaF. Z.HaqueF.KooK. M.QiaoL.RossA. G.et al (2025). Pathophysiology, noninvasive diagnostics and emerging personalized treatments for metabolic associated liver diseases. Gut Liver2 (1), 18. 10.1038/s44355-025-00030-2
140
VendrellJ.El BekayR.PeralB.Garcia-FuentesE.MegiaA.Macias-GonzalezM.et al (2011). Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology152 (11), 4072–4079. 10.1210/en.2011-1070
141
WanS.SunH. (2019). Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK/STAT3 signaling pathway. Exp. Ther. Med.17 (5), 3573–3579. 10.3892/etm.2019.7347
142
WangM. W.LuL. G. (2025). Current status of glucagon-like Peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective. J. Clin. Transl. Hepatol.13 (1), 47–61. 10.14218/JCTH.2024.00271
143
WangH.ZhangJ. (2023). The glucose metabolic reprogramming in hepatitis B virus infection and hepatitis B virus associated diseases. J. Gastroenterol. Hepatol.38 (11), 1886–1891. 10.1111/jgh.16340
144
WangC.LiQ.WangW.GuoL.GuoC.SunY.et al (2015). GLP-1 contributes to increases in PGC-1alpha expression by downregulating miR-23a to reduce apoptosis. Biochem. Biophys. Res. Commun.466 (1), 33–39. 10.1016/j.bbrc.2015.08.092
145
WangA.LiT.AnP.YanW.ZhengH.WangB.et al (2017). Exendin-4 upregulates adiponectin level in adipocytes via Sirt1/Foxo-1 signaling pathway. PLoS One12 (1), e0169469. 10.1371/journal.pone.0169469
146
WangJ.LuH.LiQ. (2024a). Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation. Front. Immunol.15, 1414594. 10.3389/fimmu.2024.1414594
147
WangL.BergerN. A.KaelberD. C.XuR. (2024b). Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology167 (4), 689–703. 10.1053/j.gastro.2024.04.029
148
WeghuberD.BarrettT.Barrientos-PerezM.GiesI.HesseD.JeppesenO. K.et al (2022). Once-weekly semaglutide in adolescents with obesity. N. Engl. J. Med.387 (24), 2245–2257. 10.1056/NEJMoa2208601
149
WeiX.ShiX.ZhongW.ZhaoY.TangY.SunW.et al (2013). Chronic alcohol exposure disturbs lipid homeostasis at the adipose tissue-liver axis in mice: analysis of triacylglycerols using high-resolution mass spectrometry in combination with in vivo metabolite deuterium labeling. PloS One8 (2), e55382. 10.1371/journal.pone.0055382
150
WeiJ. C.WuC. N.ChengW. C. (2025). Comments on association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology168 (2), 424. 10.1053/j.gastro.2024.09.039
151
WhartonS.CalannaS.DaviesM.DickerD.GoldmanB.LingvayI.et al (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes. Metab.24 (1), 94–105. 10.1111/dom.14551
152
WickramarachchiN.SoberoA.PrevalletA.DorgalliC.ShahbazO. (2025). S2830 alcohol use reduction with GLP-1 agonist use. Official Journal Am. Coll. Gastroenterology | ACG.120 (10S2), S608. 10.14309/01.ajg.0001138780.07976.e4
153
WildingJ. P. H.BatterhamR. L.CalannaS.DaviesM.Van GaalL. F.LingvayI.et al (2021). Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med.384 (11), 989–1002. 10.1056/NEJMoa2032183
154
YanC.HuW.TuJ.LiJ.LiangQ.HanS. (2023). Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease. J. Transl. Med.21 (1), 300. 10.1186/s12967-023-04166-8
155
YangF.YanS.HeY.WangF.SongS.GuoY.et al (2008). Expression of hepatitis B virus proteins in transgenic mice alters lipid metabolism and induces oxidative stress in the liver. J. Hepatol.48 (1), 12–19. 10.1016/j.jhep.2007.06.021
156
YounossiZ. M.StepanovaM.OngJ.TrimbleG.AlQahtaniS.YounossiI.et al (2021). Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States. Clin. Gastroenterol. Hepatol.19 (3), 580–9 e5. 10.1016/j.cgh.2020.05.064
157
YuX.BianX.ZhangH.YangS.CuiD.SuZ. (2023). Liraglutide ameliorates hepatic steatosis via retinoic acid receptor-related orphan receptor alpha-mediated autophagy pathway. IUBMB Life75 (10), 856–867. 10.1002/iub.2760
158
ZhangX.CaoC.ZhengF.LiuC.TianX. (2025). Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications. Cardiovasc Drugs Ther.40 (1), 287–301. 10.1007/s10557-025-07670-9
159
ZhaoH.WangL.WeiR.XiuD.TaoM.KeJ.et al (2014). Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes. Metab.16 (9), 850–860. 10.1111/dom.12291
160
ZhongW.ZhaoY.TangY.WeiX.ShiX.SunW.et al (2012). Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am. J. Pathol.180 (3), 998–1007. 10.1016/j.ajpath.2011.11.017
161
ZhouM.MokM. T.SunH.ChanA. W.HuangY.ChengA. S.et al (2017). The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene36 (29), 4135–4149. 10.1038/onc.2017.38
Summary
Keywords
alcohol-associated liver disease (ALD), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), metabolic dysfunction and alcohol-associated liver disease (MetALD), metabolic dysfunction-associated steatotic liver disease (MASLD), steatotic liver disease (SLD)
Citation
Mahalingam S, Kharbanda KK, Casey CA and Rasineni K (2026) Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum. Front. Pharmacol. 17:1752204. doi: 10.3389/fphar.2026.1752204
Received
22 November 2025
Revised
15 April 2026
Accepted
21 April 2026
Published
15 May 2026
Volume
17 - 2026
Edited by
Sathish Kumar Natarajan, University of Nebraska-Lincoln, United States
Reviewed by
Fabio Vivarelli, University of Bologna, Italy
Vijay Radhakrishnan, University of Missouri, United States
Updates
Copyright
© 2026 Mahalingam, Kharbanda, Casey and Rasineni.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Karuna Rasineni, Karuna.rasineni@unmc.edu
† These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.